Key result
Substernal EV ICD achieves successful defibrillation, pacing, and sensing without acute major complications in most patients.
Why the study?
Is the chronic implantation of a substernal extravascular implantable cardioverter-defibrillator feasible and safe?
Is the chronic implantation of a substernal extravascular implantable cardioverter-defibrillator feasible and safe?
First-in-human evaluation demonstrates that a substernal extravascular ICD is feasible and acutely safe for pacing and defibrillation.
Acute success in first-in-human testing supports substernal EV-ICD development; leaves open chronic safety and efficacy for clinical use.
This first-in-human evaluation of an EV ICD demonstrated the feasibility of substernal lead placement, defibrillation, and pacing with a chronically implanted system. There were no acute major complications, and pacing, defibrillation, and sensing performance at implantation were successful in most patients. (Extravascular ICD Pilot Study [EV ICD]; NCT03608670).
No takes yet. Share an insight, caveat, or question.
Crozier et al. (2020) studied this question. The substernal extravascular implantable cardioverter-defibrillator showed successful defibrillation, pacing, and sensing with no acute major complications in most patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: